Mitsubishi UFJ Asset Management
CYTK icon

Mitsubishi UFJ Asset Management’s Cytokinetics CYTK Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.2K Hold
589
– – ﹤0.01% 1119
2026
Q1 		$38.8K Buy
589
+500
+562% +$31.8K ﹤0.01% 1080
2025
Q4 		$5.49K Hold
89
– – ﹤0.01% 1474
2025
Q3 		$4.89K Hold
89
– – ﹤0.01% 1461
2025
Q2 		$2.94K Hold
89
– – ﹤0.01% 1552
2025
Q1 		$3.58K Hold
89
– – ﹤0.01% 1509
2024
Q4 		$4.39K Hold
89
– – ﹤0.01% 1470
2024
Q3 		$4.7K Hold
89
– – ﹤0.01% 1435
2024
Q2 		$4.82K Hold
89
– – ﹤0.01% 1381
2024
Q1 		$6.24K Hold
89
– – ﹤0.01% 1278
2023
Q4 		$7.71K Hold
89
– – ﹤0.01% 1189
2023
Q3 		$2.62K Buy
+89
New +$2.96K ﹤0.01% 1541

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Asset Management's CYTK Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 589 shares worth $50.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1119.

Mitsubishi UFJ Asset Management first reported a position in CYTK in Q3 2023 and has held it in 12 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 589 shares of Cytokinetics worth $50.2K as of Q2 2026.
  • Mitsubishi UFJ Asset Management left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #1119 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Cytokinetics in Q3 2023 and has held it in 12 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.